Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.55 |
| ▸ | CMA1 | P23946 | 5/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 2/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293993 | 1.00 | ELANE (0.55) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL7276583 | 1.00 | ELANE (0.55) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL13982069 | 1.00 | ELANE (0.55) | ELANECMA1CAPN1CTSLCTSB | |
| Sulfurous Acid SCHEMBL7313834 | 0.97 | ELANE (0.53) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL7323599 | 0.94 | ELANE (0.51) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL7313928 | 0.92 | CMA1 (0.55) | ELANECMA1 | |
| SCHEMBL7317148 | 0.89 | MALT1 (0.61) | ELANECMA1CTSLCTSBPREP | |
| SCHEMBL7324440 | 0.88 | MALT1 (0.59) | ELANECMA1 | |
| SCHEMBL17425092 | 0.87 | CMA1 (0.56) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL7320470 | 0.87 | CMA1 (0.51) | ELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289388-B2 | Methods and compositions for delivery of medicaments to the lungs | PAKA PULMONARY PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2170270-B1 | COMPOSITIONS FOR DELIVERING MEDICAMENTS INTO THE LUNGS, USES THEREOF | PAKA PULMONARY PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20140378383-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS | PAKA PULMONARY PHARMACEUTICALS, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20100284969-A1 | Methods and Compositions for Delivery of Medicaments to the Lungs | SOLMAP PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010068754-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS | PAKA PULMONARY PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2008151235-A2 | COMPOSITIONS FOR DELIVERING MEDICAMENTS INTO THE LUNGS, USES THEREOF | FORMA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284969-A1 | Methods and Compositions for Delivery of Medicaments to the Lungs | SMPD1, SMPD3, SGMS1 | ELANE 28/4885CMA1 409/4885CAPN1 1543/4885 |
| US-20140378383-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS | SMPD1, SMPD3, SGMS1 | ELANE 28/4885CMA1 409/4885CAPN1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.